147 related articles for article (PubMed ID: 19593208)
61. Hypertension due to a renin-secreting juxtaglomerular cell tumor.
Beevers DG; Maheshwari MB; Ryan PG; Moss MS; Harding LK
Am J Hypertens; 2008 Dec; 21(12):1359-61. PubMed ID: 18802431
[No Abstract] [Full Text] [Related]
62. [Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].
Pedreros-Rosales C; Jalil Milad R; Lagos Lucero M; Solari Gajardo S
Rev Med Chil; 2019 Dec; 147(12):1527-1534. PubMed ID: 32186616
[TBL] [Abstract][Full Text] [Related]
63. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH
Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036
[TBL] [Abstract][Full Text] [Related]
64. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
Gunes A; Coskun U; Boruban C; Gunel N; Babaoglu MO; Sencan O; Bozkurt A; Rane A; Hassan M; Zengil H; Yasar U
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):197-200. PubMed ID: 16445595
[TBL] [Abstract][Full Text] [Related]
65. Losartan in Cushing's syndrome.
Zacharieva S; Orbetzova M; Natchev E; Vergilova J; Andrewa M; Wipperrnann M; Torbova S; Tzingilev D; Angelova-Gateva P
Methods Find Exp Clin Pharmacol; 1998 Mar; 20(2):163-8. PubMed ID: 9604859
[TBL] [Abstract][Full Text] [Related]
66. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.
Dorado P; Beltrán LJ; Machín E; Peñas-Lledó EM; Terán E; Llerena A;
Pharmacogenomics; 2012 Nov; 13(15):1711-7. PubMed ID: 23171336
[TBL] [Abstract][Full Text] [Related]
67. Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.
Dorado P; Machín E; de Andrés F; Naranjo ME; Peñas-Lledó EM; Llerena A;
Drug Metabol Drug Interact; 2012; 27(4):217-33. PubMed ID: 23093260
[TBL] [Abstract][Full Text] [Related]
68. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.
Allabi AC; Gala JL; Horsmans Y; Babaoglu MO; Bozkurt A; Heusterspreute M; Yasar U
Clin Pharmacol Ther; 2004 Aug; 76(2):113-8. PubMed ID: 15289788
[TBL] [Abstract][Full Text] [Related]
69. Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.
Koide M; Harraz OF; Dabertrand F; Longden TA; Ferris HR; Wellman GC; Hill-Eubanks DC; Greenstein AS; Nelson MT
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34351870
[TBL] [Abstract][Full Text] [Related]
70. T allele of -344 C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension.
Lacchini R; Sabha M; Coeli FB; Favero FF; Yugar-Toledo J; Izidoro-Toledo TC; Sandrim VC; Tanus-Santos JE; de Mello MP; Moreno H
Hypertens Res; 2009 Feb; 32(2):159-62. PubMed ID: 19262476
[TBL] [Abstract][Full Text] [Related]
71. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
Han Y; Guo D; Chen Y; Chen Y; Tan ZR; Zhou HH
Eur J Clin Pharmacol; 2009 Jun; 65(6):585-91. PubMed ID: 19221727
[TBL] [Abstract][Full Text] [Related]
72. Acute effects of salmon calcitonin in man include stimulation of the renin-angiotensin-aldosterone system.
Malatino LS; Fiore CE; Foti R; Guzzardi F; Tamburino G
Miner Electrolyte Metab; 1987; 13(5):316-22. PubMed ID: 3670227
[TBL] [Abstract][Full Text] [Related]
73. [Effect of 12-week treatment with amlodipine on plasma renin activity and adrenal cortex function in patients with essential hypertension].
Kokot M; Witkowicz-Kulhawik J; Kokot F
Pol Arch Med Wewn; 1997 Aug; 98(8):93-9. PubMed ID: 9508672
[TBL] [Abstract][Full Text] [Related]
74. [Influence of dopamine receptors agonists on clinical and hemodynamic and neurohumoral indicators in hypertensive patients with concomitant obesity].
Lyzogub VH; Sobol' VO; Moshkovs'ka IuO; Bondarchuk OM
Lik Sprava; 2014; (5-6):67-72. PubMed ID: 25906649
[TBL] [Abstract][Full Text] [Related]
75. Molecular and clinical investigations in patients with low-renin hypertension.
Mackenzie IS; Brown MJ
Clin Exp Nephrol; 2009 Feb; 13(1):1-8. PubMed ID: 18704622
[TBL] [Abstract][Full Text] [Related]
76. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
J Clin Pharmacol; 2003 Jan; 43(1):84-91. PubMed ID: 12520632
[TBL] [Abstract][Full Text] [Related]
77. Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism.
Chen RN; Ho HO; Yu CY; Sheu MT
Eur J Pharm Sci; 2010 Jan; 39(1-3):82-9. PubMed ID: 19903527
[TBL] [Abstract][Full Text] [Related]
78. Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo.
Seljeflot I; Moan A; Aspelin T; Tønnessen T; Kjeldsen SE; Arnesen H
Metabolism; 1998 Mar; 47(3):292-6. PubMed ID: 9500565
[TBL] [Abstract][Full Text] [Related]
79. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
[TBL] [Abstract][Full Text] [Related]
80. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.
Yasar U; Dahl ML; Christensen M; Eliasson E
Br J Clin Pharmacol; 2002 Aug; 54(2):183-5. PubMed ID: 12207639
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
